Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223).

被引：0

作者：

Caffo, Orazio

Frantellizzi, Viviana

Tucci, Marcello

Galli, Luca

Monari, Fabio

Baldari, Sergio

Masini, Cristina

Bortolus, Roberto

Facchini, Gaetano

Alongi, Pierpaolo

Zichi, Clizia

Biasco, Elisa

Fanti, Stefano

Pignata, Salvatore

Filice, Angelina

Borsatti, Eugenio

Rossetti, Sabrina

Spada, Massimiliano

Cortesi, Enrico

De Vincentis, Giuseppe

机构：

[1] Santa Chiara Hosp, Trento, Italy

[2] Sapienza Univ Rome, Rome, Italy

[3] Osped Cardinal Massaia Asti, Asti, Italy

[4] Azienda Osped Univ Pisana, Ist Toscano Tumori, Pisa, Italy

[5] St Orsola Marcello Malpighi Hosp, Bologna, Italy

[6] Univ Messina, Messina, Italy

[7] IRCCS Reggio Emilia, AUSL, Reggio Emilia, Italy

[8] Natl Canc Ctr CRO, Aviano, Italy

[9] Pascale Fdn, Natl Canc Inst, Neaples, Italy

[10] Fdn Ist GGiglio, Cefalu, Italy

[11] San Luigi Hosp, Orbassano, Italy

[12] St Orsola Malpighi Hosp, Bologna, Italy

[13] Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Italy

[14] Natl Canc Inst, Aviano, Italy

[15] Fdn G Pascale IRCCS, Clin & Expt Uroandrol Oncol Dept, Ist Nazl Studio & Cura Tumori, Naples, Italy

[16] Fdn Ist G Giglio, UOC Oncol, Cefalu, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e17593

引用

页数：2

共 50 条

[1] Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223
Caffo, Orazio
Frantellizzi, Viviana
Tucci, Marcello
Galli, Luca
Monari, Fabio
Baldari, Sergio
Masini, Cristina
Bortolus, Roberto
Facchini, Gaetano
Alongi, Pierpaolo
Agostini, Stefania
Zichi, Clizia
Biasco, Elisa
Fanti, Stefano
Pignata, Salvatore
Filice, Angelina
Borsatti, Eugenio
Rossetti, Sabrina
Spada, Massimiliano
Cortesi, Enrico
De Vincentis, Giuseppe
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (11) : 2633 - 2638
[2] Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223
Orazio Caffo
Viviana Frantellizzi
Marcello Tucci
Luca Galli
Fabio Monari
Sergio Baldari
Cristina Masini
Roberto Bortolus
Gaetano Facchini
Pierpaolo Alongi
Stefania Agostini
Clizia Zichi
Elisa Biasco
Stefano Fanti
Salvatore Pignata
Angelina Filice
Eugenio Borsatti
Sabrina Rossetti
Massimiliano Spada
Enrico Cortesi
Giuseppe De Vincentis
[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2633 - 2638
[3] Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
Hijab, A.
Tunariu, N.
Tovey, H.
Alonzi, R.
Tree, A.
Staffurth, J.
Blackledge, M.
Padhani, A. R.
Stidwill, H.
Finch, J.
Chatfield, P.
Perry, S.
Koh, D-M.
Hall, E.
Parker, C.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S539 - S539
[4] Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).
Alonzi, Roberto
Parker, Chris C.
Tunariu, Nina
Koh, Dow-Mu
Staffurth, John
Blackledge, Matthew D.
Padhani, Anwar R.
Tree, Alison
Stidwill, Helen
Finch, Jessica
Chatfield, Peter
Perry, Sophie
Tovey, Holly
Hall, Emma
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): Results from a prospective multicentre study
Romero Laorden, N.
Lozano Mejorada, R.
Hernandez Jorge, A.
Lainez, N.
Almagro Casado, E.
Fernandez Calvo, O.
Hernando, S.
Fernandez Freire, A.
Gonzalez Billalabeitia, E.
Chirivella, I.
Garcia Dominguez, R.
Anido Herranz, U.
Vazquez Mazon, F. J.
Ros, S.
Montesa, A.
De Velasco Oria de Rueda, G. A.
Morales Barrera, R.
Lorente, D.
Castro, E.
Olmos Hidalgo, D.
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 344 - 344
[6] Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Palmedo, H.
Eschmann, S.
Werner, A.
Selinski, I.
Moellers, M-O.
Kalinovsky, J.
Benson, A.
Poeppel, T.
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 336 - 336
[7] Sarcopenia assessment in men with metastatic castration-resistant prostate cancer (mCRPC) undergoing radium 223 (Ra223) therapy
Khan, M.
Carvajal, J. Briones
Parshad, S.
Emmenegger, U.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S535 - S535
[8] Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
Palmedo, H.
Ahmadzadehfar, H.
Eschmann, S.
Selkinski, I.
Straube, F.
Niesen, A.
Schoenberger, J.
Barsegian, V.
Liepe, K.
Mottaghy, F. M.
Guan, R.
Pinkert, J.
Buetikofer, S.
Herrmann, K.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S641 - S641
[9] Osteonecrosis of the jaw (ONJ) in radium 223 (Ra223)-treated metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with exposure to zoledronic acid and/or denosumab.
Cao, Yen Thi Kim Hong
Trieu, Janson
Rojas, Vanessa
Elias, Michael
Anderson, Michael J.
Vogelzang, Nicholas J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] Safety outcomes and pain responses in the REASSURE observational study of radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Conti, Peter
George, Saby
Tomaszewski, Jeffrey
Song, Daniel
Harshman, Lauren
Nordquist, Luke
Sandstrom, Per
Bayh, Inga
Babajanyan, Svetlana
Sartor, Oliver
[J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61

← 1 2 3 4 5 →